Back to Search Start Over

Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial

Authors :
Rouze, Anahita Martin-Loeches, Ignacio Povoa, Pedro and Metzelard, Matthieu Du Cheyron, Damien Lambiotte, Fabien and Tamion, Fabienne Labruyere, Marie Geronimi, Claire Boulle and Nieszkowska, Ania Nyunga, Martine Pouly, Olivier Thille, Arnaud W. Megarbane, Bruno Saade, Anastasia Diaz, Emili and Magira, Eleni Llitjos, Jean-Francois Cilloniz, Catia and Ioannidou, Iliana Pierre, Alexandre Reignier, Jean Garot, Denis Kreitmann, Louis Baudel, Jean-Luc Fartoukh, Muriel and Plantefeve, Gaetan Beurton, Alexandra Asfar, Pierre Boyer, Alexandre Mekontso-Dessap, Armand Makris, Demosthenes and Vinsonneau, Christophe Floch, Pierre-Edouard Weiss, Nicolas and Ceccato, Adrian Artigas, Antonio Bouchereau, Mathilde and Duhamel, Alain Labreuche, Julien Nseir, Saad CoVAPid Study Grp
Publication Year :
2021

Abstract

Rationale: Early empirical antimicrobial treatment is frequently prescribed to critically ill patients with coronavirus disease (COVID-19) based on Surviving Sepsis Campaign guidelines. Objectives: We aimed to determine the prevalence of early bacterial identification in intubated patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia, as compared with influenza pneumonia, and to characterize its microbiology and impact on outcomes. Methods: A multicenter retrospective European cohort was performed in 36 ICUs. All adult patients receiving invasivemechanical ventilation.48 hours were eligible if they had SARS-CoV-2 or influenza pneumonia at ICU admission. Bacterial identification was defined by a positive bacterial culture within 48 hours after intubation in endotracheal aspirates, BAL, blood cultures, or a positive pneumococcal or legionella urinary antigen test. Measurements and Main Results: A total of 1,050 patients were included (568 in SARS-CoV-2 and 482 in influenza groups). The prevalence of bacterial identification was significantly lower in patients with SARS-CoV-2 pneumonia compared with patients with influenza pneumonia (9.7 vs. 33.6%; unadjusted odds ratio, 0.21; 95% confidence interval [CI], 0.15-0.30; adjusted odds ratio, 0.23; 95% CI, 0.16-0.33; P, 0.0001). Gram-positive cocci were responsible for 58% and 72% of coinfection in patients with SARS-CoV-2 and influenza pneumonia, respectively. Bacterial identification was associated with increased adjusted hazard ratio for 28-day mortality in patients with SARS-CoV-2 pneumonia (1.57; 95% CI, 1.01-2.44; P = 0.043). However, no significant difference was found in the heterogeneity of outcomes related to bacterial identification between the two study groups, suggesting that the impact of coinfection on mortality was not different between patients with SARS-CoV-2 and influenza. Conclusions: Bacterial identification within 48 hours after intubation is significantly less frequent in patients with SARSCoV-2 pneumonia than patients with influenza pneumonia.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.od......2127..d0c7079007be3ef3d6d0282d81dd3a57